In yesterday’s Wall Street session, Quest Diagnostics Incorporated (NYSE:DGX) shares traded at $136.24, down -5.99% from the previous session.
19 analysts cover Quest Diagnostics Incorporated (NYSE:DGX), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $165.00 and a low of $140.00, we find $145.50. Given the previous closing price of $144.92, this indicates a potential upside of 0.4 percent. DGX stock price is now -0.78% away from the 50-day moving average and -3.88% away from the 200-day moving average. The market capitalization of the company currently stands at $15.18B.
The stock has received a hold rating from 16 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $147.69 as their price target over the next twelve months.
In other news, Doherty Catherine T., SVP, Regional Businesses sold 5,307 shares of the company’s stock on Mar 07. The stock was sold for $745,899 at an average price of $140.55. Upon completion of the transaction, the SVP, Regional Businesses now directly owns 67,810 shares in the company, valued at $9.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07, SVP & General Counsel PREVOZNIK MICHAEL E sold 4,754 shares of the business’s stock. A total of $668,175 was realized by selling the stock at an average price of $140.55. This leaves the insider owning 38,527 shares of the company worth $5.25 million. Insiders disposed of 153,610 shares of company stock worth roughly $20.93 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DGX stock. In total, there are 1,215 active investors with 95.00% ownership of the company’s stock.
On Wednesday morning Quest Diagnostics Incorporated (NYSE: DGX) stock kicked off with the opening price of $138.26. During the past 12 months, Quest Diagnostics Incorporated has had a low of $120.40 and a high of $158.34. As of last week, the company has a debt-to-equity ratio of 0.66, a current ratio of 1.30, and a quick ratio of 1.20. The fifty day moving average price for DGX is $137.42 and a two-hundred day moving average price translates $141.79 for the stock.
The latest earnings results from Quest Diagnostics Incorporated (NYSE: DGX) was released for Jun, 2023. According to the Diagnostics & Research Company, earnings per share came in at $2.04, beating analysts’ expectations of $1.97 by 0.07. This compares to $3.08 EPS in the same period last year. The net profit margin was 8.20% and return on equity was 12.80% for DGX. The company reported revenue of $2.33 billion for the quarter, compared to $2.61 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.72 percent. For the current quarter, analysts expect DGX to generate $2.25B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 07/25/2023. Investors who held shares on 07/11/2023 were paid a $0.71 dividend. On an annualized basis, this represents a $2.84 dividend and a 2.08% percent yield. There was an ex-dividend date of 07/10/2023 for this dividend. In terms of dividend payout ratio, DGX is presently at 38.40%.
Quest Diagnostics Incorporated(DGX) Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
